Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818661 · ClinicalTrials.gov registry record · Phase 4
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
A Phase 4 study of Primary Progressive Aphasia and Apraxia of Speech, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01818661: Recruiting Phase 4 study of Primary Progressive Aphasia and Apraxia of Speech, sponsored by Mayo Clinic.
NCT01818661 is a Phase 4 study of Primary Progressive Aphasia and Apraxia of Speech that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 89-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01818661, a Phase 4 study of Primary Progressive Aphasia and Apraxia of Speech, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
Conditions Studied
Interventions
- DRUG AV-1451
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 4 |
What NCT01818661 shows while recruiting
NCT01818661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 89-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (44% lower).
The record links to 5 conditions, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 1 intervention - of which AV-1451 is the first listed.
NCT01818661 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01818661 about?
NCT01818661 is a clinical study titled "Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech". The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
What is the current status of trial NCT01818661?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2018-07-01. Estimated completion is 2028-06.
What conditions does trial NCT01818661 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia, Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Non-fluent Aphasia, PPA.
What interventions are being tested in trial NCT01818661?
The interventions under investigation include: AV-1451 (DRUG).
Who is sponsoring clinical trial NCT01818661?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01818661 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01818661's enrollment target sits among peer trials
50 8th of 15 higher than 8 of 15 other Primary Progressive Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Progressive Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
RECRUITING
-
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
RECRUITING · Phase 2
-
Language in Primary Progressive Aphasia
RECRUITING
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Enhancing Language Function in Aphasia
RECRUITING · NA
-
Enhancing Language Function in Primary Progressive Aphasia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI